From MarketBeat:

Argenx SE (NASDAQ:ARGX) earned an average “Moderate Buy” recommendation from 22 ratings firms. One analyst rated the stock as a sell, while 16 rated it a buy and one rated it as a strong buy. The average 1-year price projection among brokers who have recently rated the stock is $522.50.

Argenx (NASDAQ:ARGX) stock performance sees shares opening at $396.22 on Monday. The company has a market cap of $23.41 billion, a P/E ratio of -95.25, and a beta of 0.70. The 50-day simple moving average is $448.73, while the 200 day simple moving average is $468.90.

Institutional trading of argenx sees several hedge funds buying and selling shares of ARGX. JPMorgan Chase & Co. and Raymond James & Associates are among those who’ve recently grown their stakes in argenx.

Argenx SE is a biotech company that develops therapies for autoimmune diseases. Their lead candidate is efgartigimod, which is aimed at treating a variety of conditions, including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy.



Read more: argenx SE (NASDAQ:ARGX) Receives Average Recommendation of “Moderate Buy” from Analysts